Cellular Immune Tolerance Symposium

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingCellular Immune Tolerance Symposium

ALSP Community Conference: Insights and Potential of Cell-Based Therapies for the Treatment of Leukodystrophies

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingALSP Community Conference: Insights and Potential of Cell-Based Therapies for the Treatment of Leukodystrophies

“Myelin Through the Ages: Evolution, Development, Degeneration and Disease” – 2018 Gordon Research Conference (GRC) and Gordon Research Seminar (GRS)

• Post author:
• Post published:February 21, 2026
• Post category:

Continue Reading“Myelin Through the Ages: Evolution, Development, Degeneration and Disease” – 2018 Gordon Research Conference (GRC) and Gordon Research Seminar (GRS)

The 7th Annual California ALS research network and PAC10 meeting

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingThe 7th Annual California ALS research network and PAC10 meeting

HD-CARE INAUGURAL SYMPOSIUM

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingHD-CARE INAUGURAL SYMPOSIUM

California ALS Research Summit 2016

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingCalifornia ALS Research Summit 2016

A Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingA Phase 1 trial of RNDP-001, a dopaminergic progenitor drug product, in idiopathic Parkinson’s Disease

Clinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingClinical Development of ETX101, a Gene Regulation Therapy for SCN1A+ Dravet Syndrome

Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy

Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)

• Post author:
• Post published:February 21, 2026
• Post category:

Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)